{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:01:28Z","timestamp":1768932088015,"version":"3.49.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>A post-hoc analysis of the SHIFT trial was performed to explore whether ivabradine is beneficial in patients with systolic heart failure, in sinus rhythm, with resting heart rate \u226570 b.p.m., and whose guideline-recommended background therapy includes a mineralocorticoid receptor antagonist (MRA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The effect of ivabradine on the primary composite endpoint of cardiovascular death or hospitalization for worsening heart failure, and its components, was explored in 3922 SHIFT patients with MRAs at baseline vs. 2583 patients without. Patients with MRAs were younger and were more likely to have severe heart failure and less coronary artery disease or hypertension than those without these drugs. Event rates in the placebo group were higher in patients with MRAs (33%) than in those without (23%) for the primary composite endpoint, with a 40% increase in relative risk (hazard ratio 1.40, 95% confidence interval 1.22\u20131.61). This was also true for secondary endpoints related to mortality or hospitalization. The effect of ivabradine on reducing the primary endpoint was similar in patients with and without MRAs (P = 0.916 for interaction, adjusted for prognostic factors at baseline), as were its effects on cardiovascular death (P = 0.279), hospitalizations for heart failure (P = 0.304), and death from heart failure and from all causes (P = 0.723 and 0.366, respectively). There was no difference in the safety of ivabradine in the two subpopulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ivabradine improves outcomes in heart failure patients with heart rate \u226570 b.p.m. receiving multiple neurohormonal modulation treatments (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, beta-blocker, and MRA). The addition of ivabradine to multiple neurohormonal modulation should therefore be considered when the heart rate is \u226570 b.p.m.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hfs127","type":"journal-article","created":{"date-parts":[[2012,8,14]],"date-time":"2012-08-14T21:33:13Z","timestamp":1344979993000},"page":"79-84","source":"Crossref","is-referenced-by-count":22,"title":["Influence of Background Treatment with Mineralocorticoid Receptor Antagonists on Ivabradine\u2019s Effects in Patients with Chronic Heart Failure"],"prefix":"10.1093","volume":"15","author":[{"given":"Michel","family":"Komajda","sequence":"first","affiliation":[{"name":"Department of Cardiology, Universit\u00e9 Pierre et Marie Curie Paris VI , La Piti\u00e9-Salp\u00e9tri\u00e8re Hospital, 75013, Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Universit\u00e4tskliniken des Saarlandes , Klinik f\u00fcr Innere Medizin III, Homburg\/Saar ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Borer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiovascular Medicine and the Howard Gilman Institute for Heart Valve Disease, State University of New York Downstate Medical Center , Brooklyn and New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Ford","sequence":"additional","affiliation":[{"name":"Robertson Centre for Biostatistics, University of Glasgow \u00a0","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Krum","sequence":"additional","affiliation":[{"name":"Centre of Clinical Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Tase","sequence":"additional","affiliation":[{"name":"University of Pitesti, Emergency Hospital Arges, Department of Cardiology , Pitesti ,","place":["Romania"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Tavazzi","sequence":"additional","affiliation":[{"name":"Maria Cecilia Hospital\u2013GVM Care and Research, Ettore Sansavini Health Science Foundation , Cotignola ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[{"name":"Section of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg , G\u00f6teborg ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,1,27]]},"reference":[{"key":"2026011921135051200_ejhfhfs127-bib-0001","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"2026011921135051200_ejhfhfs127-bib-0002","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026011921135051200_ejhfhfs127-bib-0003","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026011921135051200_ejhfhfs127-bib-0004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026011921135051200_ejhfhfs127-bib-0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1056\/NEJMe1012547","article-title":"Aldosterone antagonists\u2014last man standing?","volume":"364","author":"Armstrong","year":"2011","journal-title":"N Engl J Med"},{"key":"2026011921135051200_ejhfhfs127-bib-0006","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"2026011921135051200_ejhfhfs127-bib-0007","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"2026011921135051200_ejhfhfs127-bib-0008","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/eurjhf\/hfq154","article-title":"EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot)","volume":"12","author":"Maggioni","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026011921135051200_ejhfhfs127-bib-0009","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/eurjhf\/hfp154","article-title":"Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f)Inhibitor Ivabradine Trial (SHIFT)","volume":"12","author":"Swedberg","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026011921135051200_ejhfhfs127-bib-0010","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","article-title":"ESC Guidelines for the diagnosis treatment of acute chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)","volume":"10","author":"Dickstein","year":"2008","journal-title":"Eur J Heart Fail"},{"issue":"suppl 1","key":"2026011921135051200_ejhfhfs127-bib-0011","first-page":"590","article-title":"Heart rate is a powerful predictor of mortality in post-AMI patients with heart failure: results from the EPHESUS trial. Abstract 3632","volume":"27","author":"Deedwania","year":"2006","journal-title":"Eur Heart J"},{"key":"2026011921135051200_ejhfhfs127-bib-0012","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"Bohm","year":"2010","journal-title":"Lancet"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfs127","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfs127","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1093\/eurjhf\/hfs127","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1093\/eurjhf\/hfs127","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/15\/1\/79\/66443343\/eurjhf_15_1_79.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/15\/1\/79\/66443343\/eurjhf_15_1_79.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:16:03Z","timestamp":1768875363000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/15\/1\/79\/8428613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,1]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,27]]},"published-print":{"date-parts":[[2013,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hfs127","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,1]]},"published":{"date-parts":[[2013,1,1]]}}}